A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
第1相
完了
NCT06023095
| 対象疾患 | Overweight, Obesity |
|---|
| 相 | 第1相 |
|---|
| スポンサー | Eli Lilly and Company |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 24 名 |
|---|
| 介入（薬剤） | LY3502970 |
|---|
| 開始日 | 2023年9月21日 |
|---|
| 完了日 | 2024年7月29日 |
|---|
| 結果公開日 | 2026年7月17日 |
|---|
概要
The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive LY3502970, or placebo given orally. For each participant, the study will last about approximately 22- and 30-weeks for both cohort 1 and 2, respectively including screening period.
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Baseline through Week 18 (Cohort 1) & Week 26 (Cohort 2) · Participants
| LY3502970 (Cohort 1) | 10 Participants |
|---|
| LY3502970 (Cohort 2) | 8 Participants |
|---|
| Placebo | 3 Participants |
|---|
| LY3502970 (Cohort 1) | 0 Participants |
|---|
| LY3502970 (Cohort 2) | 0 Participants |
|---|
| Placebo | 0 Participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。